Skip to main content
. 2015 Feb 3;5:7835. doi: 10.1038/srep07835

Figure 5. Western blot results for the expression of molecules in the MAPK pathway.

Figure 5

(A): The expression of Ras, MEK1/2, and p-ERK1/2 in the M/T group was significantly enhanced compared with the expression levels detected in the M0 group. Treatment with 10 μg/mL Gefitinib for 48 h significantly reduced the expression of Ras, MEK1/2, and p-ERK1/2 compared with the expression levels detected in the M/T group. (B): Histograms of protein expression for Ras, MEK1/2, and p-ERK1/2. All the experiments were repeated three times.*denotes p < 0.05.